Table 2 Primary analysis
Screened for Chlamydia | No screening | |
|---|---|---|
8% Prevalence | ||
Cost§ | 256,305,162 | 131,664,935 |
Treated Chlamydia | 496,241 | 167,562 |
PID | 6393 | 23,658 |
SAB | 3 | 10 |
Vertical Transmission | 8211 | 37,050 |
Neonatal conjunctivitis | 6806 | 29,755 |
Pneumonia | 3093 | 13,585 |
Premature | 3 | 6 |
Infertility | 786 | 2910 |
WTP: | 19.34 | --- |
6.7% Prevalence | ||
Cost | 249,087,114 | 106,421,100 |
Treated Chlamydia | 204,632 | 66,819 |
PID | 2673 | 9852 |
SAB | 3 | 9 |
Vertical Transmission | 4999 | 15,427 |
Neonatal conjunctivitis | 4101 | 12,386 |
Pneumonia | 1863 | 5659 |
Premature | 2 | 1 |
Infertility | 329 | 1222 |
WTP: | 22.14 | --- |
Threshhold-.169 prevalence | ||
Cost§ | 279,158,019 | 279,151,574 |
Treated Chlamydia | 1,044,039 | 348,013 |
PID | 6528 | 49,985 |
SAB | 6 | 21 |
Vertical transmission | 9757 | 78,264 |
Neonatal conjunctivitis | 8301 | 62,855 |
Pneumonia | 3738 | 28,718 |
Premature | 5 | 19 |
Infertility | 810 | 6198 |
WTP: | 0 | --- |